3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients

I. R. N. Verly; A. B. P. van Kuilenburg; N. G. G. M. Abeling; S. M. I. Goorden; M. Fiocco; F. M. Vaz; M. M. van Noesel; C. M. Zwaan; G. J. L. Kaspers; J. H. M. Merks; H. N. Caron; G. A. M. Tytgat

doi:10.1016/j.ejca.2017.11.025

3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients

I. R. N. Verly
, A. B. P. van Kuilenburg
, N. G. G. M. Abeling
, S. M. I. Goorden
, M. Fiocco
, F. M. Vaz
, M. M. van Noesel
, C. M. Zwaan
, G. J. L. Kaspers
, J. H. M. Merks
, H. N. Caron
, G. A. M. Tytgat

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	102-110
Journal	European Journal of Cancer
Volume	90
DOIs	https://doi.org/10.1016/j.ejca.2017.11.025
Publication status	Published - Feb 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.ejca.2017.11.025

Cite this

Verly, I. R. N., van Kuilenburg, A. B. P., Abeling, N. G. G. M., Goorden, S. M. I., Fiocco, M., Vaz, F. M., van Noesel, M. M., Zwaan, C. M., Kaspers, G. J. L., Merks, J. H. M., Caron, H. N., & Tytgat, G. A. M. (2018). 3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients. European Journal of Cancer, 90, 102-110. https://doi.org/10.1016/j.ejca.2017.11.025

@article{92e01673278f4bc79397e4cc3597136d,

title = "3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients",

author = "Verly, \{I. R. N.\} and \{van Kuilenburg\}, \{A. B. P.\} and Abeling, \{N. G. G. M.\} and Goorden, \{S. M. I.\} and M. Fiocco and Vaz, \{F. M.\} and \{van Noesel\}, \{M. M.\} and Zwaan, \{C. M.\} and Kaspers, \{G. J. L.\} and Merks, \{J. H. M.\} and Caron, \{H. N.\} and Tytgat, \{G. A. M.\}",

year = "2018",

month = feb,

doi = "10.1016/j.ejca.2017.11.025",

language = "English",

volume = "90",

pages = "102--110",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

}

Verly, IRN, van Kuilenburg, ABP, Abeling, NGGM, Goorden, SMI, Fiocco, M, Vaz, FM, van Noesel, MM, Zwaan, CM, Kaspers, GJL, Merks, JHM, Caron, HN & Tytgat, GAM 2018, '3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients', European Journal of Cancer, vol. 90, pp. 102-110. https://doi.org/10.1016/j.ejca.2017.11.025

TY - JOUR

T1 - 3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients

AU - Verly, I. R. N.

AU - van Kuilenburg, A. B. P.

AU - Abeling, N. G. G. M.

AU - Goorden, S. M. I.

AU - Fiocco, M.

AU - Vaz, F. M.

AU - van Noesel, M. M.

AU - Zwaan, C. M.

AU - Kaspers, G. J. L.

AU - Merks, J. H. M.

AU - Caron, H. N.

AU - Tytgat, G. A. M.

PY - 2018/2

Y1 - 2018/2

U2 - 10.1016/j.ejca.2017.11.025

DO - 10.1016/j.ejca.2017.11.025

M3 - Article

C2 - 29274926

SN - 0959-8049

VL - 90

SP - 102

EP - 110

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -